With the regenerative medicine market expected by many analysts to explode in value to more than $35 billion by 2019, biotech innovators Rainbow Coral Corp. (OTCBB: RBCC) are targeting incredible new breakthroughs in the industry ripe for marketing and development.
Forecasters across the globe are calling regenerative health the future of medicine, and with good reason. In recent years, major discoveries in the usage of adult stem cells and biologics have led to promising advances in the treatment of illnesses from chronic back pain to leukemia and even AIDS.
With new, uniquely patentable regenerative therapies being developed all over the U.S., RBCC is reaching out to emerging industry leaders regarding development partnerships that could significantly boost the company’s bottom line.
“So many current medical treatments focus on reducing pain and suffering rather than addressing their cause,” said RBCC CEO Patrick Brown. “A market revolution is now underway as new advances allow us increasingly to repair afflicted organs and systems using non-invasive methods. It’s a new day in healthcare.”
By acquiring or partnering with up-and-coming regenerative therapy companies, RBCC plans to be well-positioned to capitalize on the big growth in store for the industry. The company invests in technology developed to compete in the biotechnology industry alongside Amgen (NASDAQ: AMGN), Dendreon Corporation (NASDAQ: DNDN), Smith & Nephew (NYSE: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).
For more information on RBCC’s other biotech initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Patrick Brown, 850-269-7230
President and CEO